Key Takeaways
- • IMM Private Equity terminated acquisition negotiations for CGBio, a regenerative medicine company specializing in spine and wound-care materials owned by Daewoong Pharmaceutical, after failing to resolve contractual disagreements between both parties.
- • The collapsed deal valued CGBio at approximately $730 million (1.1 trillion won) for up to an 80% equity stake, representing a significant missed transaction in South Korea's biomedical device sector.
- • Contractual disputes over specific clauses proved insurmountable, forcing both parties to abandon exclusive negotiations despite IMM PE's previous selection as the preferred bidder.
- • The transaction failure eliminates planned capital infusion into a specialized regenerative medicine platform and signals potential challenges in biotech M&A execution within South Korea's healthcare sector.
Summary
IMM Private Equity, one of South Korea's largest private equity firms, has terminated its acquisition talks for CGBio Co., a spine and wound-care materials manufacturer and affiliate of pharmaceutical conglomerate Daewoong Pharmaceutical. The deal collapse follows failed negotiations over unresolved contract clauses between the two parties, marking an unexpected reversal after IMM PE had been selected as the preferred bidder for the transaction.
The proposed acquisition would have valued CGBio at up to $730 million (approximately 1.1 trillion won), with IMM PE securing up to an 80% equity stake in the regenerative medicine company. Earlier agreements had specified an initial 51% stake acquisition as the foundation of the broader transaction structure. CGBio operates in the specialized biomedical device space, focusing on regenerative materials for spinal and dental applications—segments representing higher-margin opportunities within South Korea's medical technology ecosystem.
The transaction was led by Yoon Jae-seung, former chairman of Daewoong Pharmaceutical and a second-generation member of the founding family, who had driven the strategic sale process. Despite securing exclusive negotiating rights and advancing toward definitive agreements, the parties could not reconcile fundamental contractual requirements, ultimately forcing both to withdraw from exclusive negotiations.
The failed deal reflects broader challenges in biotech and medical device M&A execution, where valuation consensus may mask structural disagreements on earnouts, indemnification provisions, regulatory representations, or post-acquisition governance rights. For institutional investors and LPs tracking South Korean life sciences consolidation, the CGBio transaction collapse signals that deal certainty remains elusive even with preferred-bidder status and preliminary price alignment.
The proposed acquisition would have valued CGBio at up to $730 million (approximately 1.1 trillion won), with IMM PE securing up to an 80% equity stake in the regenerative medicine company. Earlier agreements had specified an initial 51% stake acquisition as the foundation of the broader transaction structure. CGBio operates in the specialized biomedical device space, focusing on regenerative materials for spinal and dental applications—segments representing higher-margin opportunities within South Korea's medical technology ecosystem.
The transaction was led by Yoon Jae-seung, former chairman of Daewoong Pharmaceutical and a second-generation member of the founding family, who had driven the strategic sale process. Despite securing exclusive negotiating rights and advancing toward definitive agreements, the parties could not reconcile fundamental contractual requirements, ultimately forcing both to withdraw from exclusive negotiations.
The failed deal reflects broader challenges in biotech and medical device M&A execution, where valuation consensus may mask structural disagreements on earnouts, indemnification provisions, regulatory representations, or post-acquisition governance rights. For institutional investors and LPs tracking South Korean life sciences consolidation, the CGBio transaction collapse signals that deal certainty remains elusive even with preferred-bidder status and preliminary price alignment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.